TY - GEN AU - Gunjan Dagar AU - Ashna Gupta AU - Tariq Masoodi AU - Sabah Nisar AU - Maysaloun Merhi AU - Sheema Hashem AU - Ravi Chauhan AU - Manisha Dagar AU - Sameer Mirza AU - Puneet Bagga AU - Rakesh Kumar AU - Ammira S Al-Shabeeb Akil TI - Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. PY - 2023/// CY - [Place of publication not identified] PB - BMC KW - Tumor antigens KW - Immunotherapy KW - Hematological malignancy KW - Solid tumor KW - Cytokine Release Syndrome KW - Antigen Escape KW - B. Sc. Medical Laboratory Science KW - UMUN open access collection KW - hematology KW - Review articles N1 - The source lists 17 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest; Publication type: Review article; Linked open-access copy: published version; Open access; no subscription required for the linked open-access version N2 - Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells UR - https://europepmc.org/articles/PMC10327392 ER -